SHAREHOLDER ALERT: Weiss Law Investigates Biohaven Pharmaceutical Holding Company Ltd.

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" or the "Company") (NYSE: BHVN) in connection with the proposed acquisition of the Company by Pfizer Inc. ("Pfizer") (NYSE: PFE). Under the terms of the merger agreement, Pfizer will acquire all outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in cash. Biohaven common shareholders, including Pfizer, will also receive 0.5 of a share of New Biohaven per Biohaven common share, a new publicly traded company that will retain Biohaven's non-calcitonin gene-related peptide development stage pipeline compounds.

If you own Biohaven shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:
https://www.weisslaw.co/news-and-cases/bhvn
Or please contact:
Joshua Rubin, Esq.
Weiss Law
305 Broadway, 7 th Floor
New York , NY  10007
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

Weiss Law is investigating whether (i) Biohaven's board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the per-share merger consideration adequately compensates Biohaven's shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/shareholder-alert-weiss-law-investigates-biohaven-pharmaceutical-holding-company-ltd-301544263.html

SOURCE Weiss Law

News Provided by PR Newswire via QuoteMedia

PFE
The Conversation (0)
Arvinas and Pfizer Announce Upcoming Vepdegestrant  Poster Presentations at the 2023 European Society for Medical Oncology  Breast Cancer Annual Congress

Arvinas and Pfizer Announce Upcoming Vepdegestrant Poster Presentations at the 2023 European Society for Medical Oncology Breast Cancer Annual Congress

Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated data related to vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress. Vepdegestrant is a novel investigational PROTAC ® estrogen receptor... Keep Reading...
Pfizer Reports First-Quarter 2023 Results

Pfizer Reports First-Quarter 2023 Results

First-Quarter 2023 Revenues of $18.3 Billion Expected Decline in Comirnaty (1) Revenue Drove 26% Operational Decrease in First-Quarter 2023 Revenues First-Quarter 2023 Revenues from Comirnaty (1) and Paxlovid of $7.1 Billion Excluding Contributions from Comirnaty (1) and Paxlovid, Revenues Grew... Keep Reading...
XTANDI®  plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide

XTANDI® plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide

Data from Phase 3 EMBARK trial to be presented as a plenary session during the 2023 American Urological Association Annual Meeting Results show the potential for XTANDI to add to the standard of care in prostate cancer, if approved Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki... Keep Reading...
U.S. FDA Approves PREVNAR 20®, Pfizer's 20-valent Pneumococcal Conjugate Vaccine for Infants and Children

U.S. FDA Approves PREVNAR 20®, Pfizer's 20-valent Pneumococcal Conjugate Vaccine for Infants and Children

PREVNAR 20 offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine, helping to protect against all 20 serotypes contained in the vaccine PREVNAR 20 builds on PREVNAR 13 ® and includes seven additional serotypes shown to be associated with antibiotic resistance,... Keep Reading...
Pfizer Declares Second-Quarter 2023 Dividend

Pfizer Declares Second-Quarter 2023 Dividend

Board of Directors approves quarterly cash dividend of $0.41 per share Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.41 second-quarter 2023 dividend on the company's common stock, payable June 9, 2023, to holders of the Common Stock of record at the close of... Keep Reading...
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT

Charles River Associates (CRA) to evaluate epidemiology, pricing, prescriber dynamics, and market access potential for Bria-IMT in metastatic breast cancer in the USKaleio to support brand strategies and customized commercial-readiness solutionsBria-IMT is currently being evaluated in... Keep Reading...
Syringes with measurement markings overlaid with a fluctuating blue and white line graph.

Zymeworks Expands into Respiratory Market with Theravance Buyout

Oncology-focused drugmaker Zymeworks (NASDAQ:ZYME) has agreed to acquire Theravance Biopharma (NASDAQ:TBPH) for US$929 million in cash, expanding its portfolio into the respiratory segment.The acquisition delivers Zymeworks a 35 percent US net profit share in Yupelri, the first and only... Keep Reading...
Rows of multicolored test tubes with brown, purple, blue and green caps arranged neatly on a white rack.

Merck KGaA to Acquire Bio-Techne in US$11.3 Billion Deal

Merck KGaA (ETR:MRK,OTCPL:MKGAF) has agreed to acquire life sciences supplier Bio-Techne (NASDAQ:TECH) for US$11.3 billion in cash, marking the firm’s largest transaction in a decade.Under a definitive agreement announced on Thursday (June 25), Merck KGaA will pay US$73 per share, representing a... Keep Reading...
BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT

Agreement supports potential commercial readiness for Bria-IMT using Uneedle's proprietary microneedle technology for intradermal administration Technology is currently used in BriaCell's pivotal Phase 3 study and is designed to support faster, more convenient administration while enhancing the... Keep Reading...
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs for Investors in 2026

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies and the pharma market as a whole. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the... Keep Reading...
InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the third quarter of the fiscal year 2026... Keep Reading...

Interactive Chart

Latest Press Releases

Related News